Trpc ion channel inhibitors for use in therapy
OwnerDavid John BEECH, Richard James FOSTER +2inventors
InventorsDavid John BEECH, Richard James FOSTER, Sin Ying CHEUNG, Baptiste Michel RODE
Life of this patent
Estimating the term…
Abstract
Described herein are inhibitors Transient Receptor Potential Canonical (TRPC) ion channels comprising TRPC4 protein and/or TRPC5 protein for use in combating obesity and other medical conditions including insulin resistance associated with Type II diabetes or development of Type II diabetes (pre-diabetes), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Also disclosed is the use of the inhibitors for cosmetic purposes, such as cosmetic weight loss.
Claims25
An inhibitor which directly targets a Transient Receptor Potential Canonical (TRPC) ion channel comprising TRPC4 and/or TRPC5 as present in adipocytes for use in the treatment or prophylaxis of a condition selected from obesity, insulin resistance, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
A compound of the formula (X), or a pharmaceutically acceptable salt thereof:
- wherein R1 and R2 are independently H or C1-4 alkyl.
-28. (canceled)
Dependencies are inferred from the claim text.